Macerich Company (The) Common Stock vs Novavax Inc — how do they compare? Macerich Company (The) Common Stock trades at $22.18 (market cap $6.29B), while Novavax Inc trades at $12.41 (market cap $2.08B). The key difference: Macerich Company (The) Common Stock is far larger — about 3× Novavax Inc's market cap, and Macerich Company (The) Common Stock pays a 3.07% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Macerich Company (The) Common Stock for 0 Days and Novavax Inc for 59 Days on average.
| MAC | NVAX | |
|---|---|---|
Market Cap | $6.29B | $2.08B |
Volume | 3,158,142 | 8,501,139 |
Sector | Real Estate | Health |
52-Week High | $26.51 | $12.82 |
52-Week Low | $16.20 | $6.22 |
Typical Hold Time | 0 Days | 59 Days |
Enterprise Value | $10.97B | $1.66B |
Dividend Yield | 3.07% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novavax (NVAX) trades at $12.82, up 1.26% on the day, with a bullish technical signal and strong analyst support. Recent earnings beats and strategic pivots toward its Matrix-M adjuvant platform and partnerships, such as with Sanofi for COVID-19 vaccines, highlight operational progress. However, negative cash flows and a net loss in 2026 projections underscore financial volatility amid transitioning revenue streams.
The outlook balances near-term catalysts from vaccine approvals and partnership momentum against persistent cash burn and competitive pressures. Investors face opportunity in undervalued metrics like a low P/E of 3.14, but risks include execution hurdles and dependency on successful licensing deals to achieve sustainable profitability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
The Macerich Company is a real estate investment trust that owns, operates, and redevelops shopping centers concentrated in California, the Pacific Northwest, and other major US markets.
Read more on MAC →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →